Evidence map›Paper›PMID 32744862›Full record

Trial reportAnnals of internal medicine2020

Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial.

Matthias Schieker, Philip G Conaghan, Linda Mindeholm, Jens Praestgaard, Daniel H Solomon, Celeste Scotti, Herman Gram, Tom Thuren, Ronenn Roubenoff, Paul M Ridker

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01327846 (A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP), which is not on this map. Cited by 97 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 1 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01327846 phase3completednot on this map

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

TypeinterventionalSponsorNovartis PharmaceuticalsRan2011 to 2019Enrolled10,066ConditionsAtherosclerosisArmsCanakinumab, Placebo, Standard of care
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 1 synthesis or guideline pooled it, 153 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Emerging therapies for knee osteoarthritis.Nature reviews. Rheumatology · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Observational
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Osteoarthritis as a systemic disease.Nature reviews. Rheumatology · 2026
    Review
  19. Review
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 4 countries.

Matthias SchiekerNovartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland, and Ludwig Maximilian University of Munich, Munich, Germany (M.S.).ORCID 0000-0002-1230-3653
Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds BiomedicalResearch Centre, Leeds, United Kingdom (P.G.C.).ORCID 0000-0002-3478-5665
Linda MindeholmNovartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland (L.M., J.P., C.S., H.G., R.R.).
Jens PraestgaardNovartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland (L.M., J.P., C.S., H.G., R.R.).
Daniel H SolomonBrigham and Women's Hospital, Boston, Massachusetts (D.H.S., P.M.R.).
Celeste ScottiNovartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland (L.M., J.P., C.S., H.G., R.R.).
Herman GramNovartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland (L.M., J.P., C.S., H.G., R.R.).
Tom ThurenNovartis Pharma AG, Basel, Switzerland (T.T.).ORCID 0000-0001-6327-3493
Ronenn RoubenoffNovartis Institutes for Biomedical Research, Cambridge, Massachusetts, and Basel, Switzerland (L.M., J.P., C.S., H.G., R.R.).ORCID 0000-0002-3959-3179
Paul M RidkerBrigham and Women's Hospital, Boston, Massachusetts (D.H.S., P.M.R.).
Novartis (Switzerland) · CHBrigham and Women's Hospital · USUniversity of Leeds · GB

Funding

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
NIAMS NIH HHS P30 AR072577
6 · The paper itself

Abstract

backgroundOsteoarthritis is a common inflammatory disorder with no disease-modifying therapies. Whether inhibition of interleukin-1β (IL-1β) can reduce the consequences of large joint osteoarthritis is unclear.

objectiveTo determine whether IL-1β inhibition with canakinumab reduces incident total hip or knee replacement (THR/TKR).

designExploratory analysis of a randomized trial. (ClinicalTrials.gov: NCT01327846).

setting1091 clinical sites in 39 countries.

participants10 061 CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) participants.

interventionRandom allocation to placebo or canakinumab (50, 150, or 300 mg) subcutaneously once every 3 months. MEASUREMENTS: The primary and secondary outcomes were time to first incident THR/TKR and time to first occurrence of an osteoarthritis-related adverse event (AE). Data were obtained through blinded ascertainment of trial clinical and safety databases.

resultsMedian follow-up was 3.7 years. For the individual canakinumab dose groups, compared with placebo, hazard ratios (HRs) for incident THR/TKR during follow-up were 0.60 (95% CI, 0.38 to 0.95) for the 50-mg group, 0.53 (CI, 0.33 to 0.84) for the 150-mg group, and 0.60 (CI, 0.38 to 0.93) for the 300-mg group. Thus, in the pooled canakinumab groups, compared with the placebo group, incidence rates for THR/TKR were 0.31 and 0.54 events per 100 person-years (HR, 0.58 [CI, 0.42 to 0.80]; LIMITATION: Because the parent trial was not designed to examine the efficacy of IL-1β inhibitors in osteoarthritis, information on structural joint outcomes was not collected.

conclusionFindings from this exploratory analysis of a randomized controlled trial support further investigation of IL-1β inhibition for treatment of large joint osteoarthritis. PRIMARY FUNDING SOURCE: Novartis Pharmaceuticals.

Indexed as

Antibodies, Monoclonal, HumanizedArthroplasty, Replacement, HipArthroplasty, Replacement, KneeDouble-Blind MethodFemaleHumansIncidenceInterleukin-18MaleMiddle AgedOsteoarthritis, HipOsteoarthritis, KneeAntibodies, Monoclonal, HumanizedcanakinumabIL18 protein, humanInterleukin-18

Identifiers

PMID32744862
PMCPMC8503784
OpenAlexW3046964613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.